Cefiderocol for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model.

WOODS, Beth, SCHMITT, Laetitia, JANKOVIC, Dina, KEARNS, Benjamin, SCOPE, Alison, REN, Shijie, SRIVASTAVA, Tushar, KU, Chu Chang, HAMILTON, Jean, ROTHERY, Claire, BOJKE, Laura, SCULPHER, Mark and HARNAN, Sue (2024). Cefiderocol for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model. Health technology assessment (Winchester, England), 28 (28), 1-238.

Preview

PDF Scope-CefiderocolForTreatingSevere(VoR).pdf - Published Version Creative Commons Attribution. Download (3MB) | Preview

Abstract

Background

To limit the use of antimicrobials without disincentivising the development of novel antimicrobials, there is interest in establishing innovative models that fund antimicrobials based on an evaluation of their value as opposed to the volumes used. The aim of this project was to evaluate the population-level health benefit of cefiderocol in the NHS in England, for the treatment of severe aerobic Gram-negative bacterial infections when used within its licensed indications. The results were used to inform the National Institute for Health and Care Excellence guidance in support of commercial discussions regarding contract value between the manufacturer and NHS England.

Methods

The health benefit of cefiderocol was first derived for a series of high-value clinical scenarios. These represented uses that were expected to have a significant impact on patients' mortality risks and health-related quality of life. The clinical effectiveness of cefiderocol relative to its comparators was estimated by synthesising evidence on susceptibility of the pathogens of interest to the antimicrobials in a network meta-analysis. Patient-level costs and health outcomes of cefiderocol under various usage scenarios compared with alternative management strategies were quantified using decision modelling. Results were reported as incremental net health effects expressed in quality-adjusted life-years, which were scaled to 20-year population values using infection number forecasts based on data from Public Health England. The outcomes estimated for the high-value clinical scenarios were extrapolated to other expected uses for cefiderocol.

Results

Among Enterobacterales isolates with the metallo-beta-lactamase resistance mechanism, the base-case network meta-analysis found that cefiderocol was associated with a lower susceptibility relative to colistin (odds ratio 0.32, 95% credible intervals 0.04 to 2.47), but the result was not statistically significant. The other treatments were also associated with lower susceptibility than colistin, but the results were not statistically significant. In the metallo-beta-lactamase Pseudomonas aeruginosa base-case network meta-analysis, cefiderocol was associated with a lower susceptibility relative to colistin (odds ratio 0.44, 95% credible intervals 0.03 to 3.94), but the result was not statistically significant. The other treatments were associated with no susceptibility. In the base case, patient-level benefit of cefiderocol was between 0.02 and 0.15 quality-adjusted life-years, depending on the site of infection, the pathogen and the usage scenario. There was a high degree of uncertainty surrounding the benefits of cefiderocol across all subgroups. There was substantial uncertainty in the number of infections that are suitable for treatment with cefiderocol, so population-level results are presented for a range of scenarios for the current infection numbers, the expected increases in infections over time and rates of emergence of resistance. The population-level benefits varied substantially across the base-case scenarios, from 896 to 3559 quality-adjusted life-years over 20 years.

Conclusion

This work has provided quantitative estimates of the value of cefiderocol within its areas of expected usage within the NHS.

Limitations

Given existing evidence, the estimates of the value of cefiderocol are highly uncertain.

Future work

Future evaluations of antimicrobials would benefit from improvements to NHS data linkages; research to support appropriate synthesis of susceptibility studies; and application of routine data and decision modelling to assess enablement value.

Study registration

No registration of this study was undertaken.

Funding

This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment Policy Research Programme (NIHR award ref: NIHR135591), conducted through the Policy Research Unit in Economic Methods of Evaluation in Health and Social Care Interventions, PR-PRU-1217-20401, and is published in full in Health Technology Assessment; Vol. 28, No. 28. See the NIHR Funding and Awards website for further award information.

Item Type:	Article
Uncontrolled Keywords:	Humans; Gram-Negative Bacterial Infections; Cephalosporins; Anti-Bacterial Agents; Quality-Adjusted Life Years; Quality of Life; Cost-Benefit Analysis; State Medicine; Technology Assessment, Biomedical; England; Cefiderocol; ANTIBACTERIAL AGENTS; BACTERIAL; BETA-LACTAMASES; CEFIDEROCOL; COLISTIN; COST-EFFECTIVENESS ANALYSIS; COST–BENEFIT ANALYSIS; DRUG RESISTANCE; EXPERT ELICITATION; GRAM-NEGATIVE BACTERIAL INFECTIONS; MICROBIAL SENSITIVITY TESTS; NETWORK META-ANALYSIS; OXACILLINASE; PSEUDOMONAS AERUGINOSA; QUALITY-ADJUSTED LIFE-YEARS; SYSTEMATIC REVIEW; Humans; Cephalosporins; Anti-Bacterial Agents; Quality-Adjusted Life Years; Cost-Benefit Analysis; England; Technology Assessment, Biomedical; Cefiderocol; Gram-Negative Bacterial Infections; State Medicine; Quality of Life; 0806 Information Systems; 0807 Library and Information Studies; 1117 Public Health and Health Services; Health Policy & Services; 4203 Health services and systems; 4206 Public health
Identification Number:	https://doi.org/10.3310/ygwr4511
Page Range:	1-238
SWORD Depositor:	Symplectic Elements
Depositing User:	Symplectic Elements
Date Deposited:	22 Jul 2024 13:03
Last Modified:	22 Jul 2024 13:15
URI:	https://shura.shu.ac.uk/id/eprint/33971

Actions (login required)

View Item

Downloads

Publication Metrics